The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at ...

The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of ...

SPRING HOUSE, PA – Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S ...

Johnson & Johnson (JNJ) announced the submission of a supplemental Biologics License Application to the FDA seeking approval of a ...

Johnson & Johnson seeks US FDA approval for subcutaneous induction regimen of Tremfya in ulcerative colitis: Spring House, Pennsylvania Monday, November 25, 2024, 11:00 Hrs [IST] ...

5. The guidance recommends advanced or immunomodulatory therapy after failure of 5-aminosalicylates instead of a "step-up" approach. The recommendations also define moderate to severe disease using a ...

Notable news about inflammatory bowel disease (IBD) in 2024 included a study evaluating loss of response to tumor necrosis ...

Ulcerative colitis in children is often characterized by extensive colitis with a cumulative rate of colectomy up to 40% at 10 years. Scheduled combination therapy with anti-TNF (and pretreatment ...

Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as ... other biologic therapies or Pfizer's JAK ...

“Even with the introduction of biologic treatments in recent years, there is still a large unmet medical need in ulcerative colitis, as too many patients do not respond or stop responding to ...